{"id":"cortancyl-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia / glucose intolerance"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis / bone loss"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Insomnia / mood changes"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Cushingoid features (with chronic use)"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cortancyl (prednisone) is a systemic corticosteroid that acts as a glucocorticoid receptor agonist, reducing the production and activity of inflammatory cytokines and immune cells. It is used to manage various inflammatory and autoimmune conditions by broadly suppressing immune-mediated inflammation. The drug crosses cell membranes and binds intracellular glucocorticoid receptors, modulating gene transcription related to inflammation.","oneSentence":"Cortancyl is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:40.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Hematologic malignancies and lymphomas (as adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT04662580","phase":"PHASE1","title":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-03","conditions":"Metastatic Prostate Cancer","enrollment":183},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT06246513","phase":"PHASE3","title":"A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-01-15","conditions":"Limb-girdle Muscular Dystrophy","enrollment":17},{"nctId":"NCT01931696","phase":"NA","title":"Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-08","conditions":"Asthma","enrollment":200},{"nctId":"NCT06860243","phase":"PHASE1","title":"A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Hepatic Impairment, Healthy Participants","enrollment":16},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT01314118","phase":"PHASE2","title":"IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2011-05-04","conditions":"Prostate Cancer, Prostatic Neoplasm","enrollment":131},{"nctId":"NCT07418177","phase":"PHASE1, PHASE2","title":"Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-10","conditions":"AMD - Age-Related Macular Degeneration","enrollment":9},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":"Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases","enrollment":45},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT07311694","phase":"PHASE3","title":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-02","conditions":"PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer","enrollment":370},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT06452537","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-07-09","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","enrollment":102},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT03128905","phase":"PHASE3","title":"Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis","status":"COMPLETED","sponsor":"Lille Catholic University","startDate":"2018-02-05","conditions":"Chondrocalcinosis","enrollment":111},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT03589326","phase":"PHASE3","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2018-10-04","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","enrollment":245},{"nctId":"NCT01961843","phase":"NA","title":"Abiraterone Acetate for Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01-14","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT06814132","phase":"PHASE1","title":"A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-07","conditions":"Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic","enrollment":24},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT03790332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2018-11-19","conditions":"Chronic Graft Versus Host Disease","enrollment":59},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT06143891","phase":"PHASE3","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-23","conditions":"Chronic Graft Versus Host Disease","enrollment":260},{"nctId":"NCT04520451","phase":"PHASE2","title":"Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-08-22","conditions":"Immunoglobulin G4 Related Disease","enrollment":27},{"nctId":"NCT05276492","phase":"PHASE1","title":"Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-01-24","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":50},{"nctId":"NCT03545464","phase":"PHASE3","title":"COrticosteroids in acUte uRticAria in emerGency dEpartment","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-21","conditions":"Urticaria, Angiœdema","enrollment":137},{"nctId":"NCT05588609","phase":"PHASE2","title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","status":"TERMINATED","sponsor":"Merus B.V.","startDate":"2022-11-17","conditions":"NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer","enrollment":13},{"nctId":"NCT05658640","phase":"PHASE1, PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT05916586","phase":"NA","title":"Effect of Short-term Prednisone Therapy on C-reactive Protein in Patients With Acute Heart Failure","status":"COMPLETED","sponsor":"Heart Initiative","startDate":"2023-08-11","conditions":"Acute Heart Failure","enrollment":101},{"nctId":"NCT07159893","phase":"NA","title":"Inectolizumab With Steroid Optimization in Newly Treated NMOSD","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-09","conditions":"Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS","enrollment":25},{"nctId":"NCT03139604","phase":"PHASE3","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-07-19","conditions":"Graft-versus-host Disease (GVHD)","enrollment":439},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT03348670","phase":"PHASE2, PHASE3","title":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2023-08-18","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT07124936","phase":"PHASE1, PHASE2","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":97},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT06952686","phase":"PHASE3","title":"A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants","status":"WITHDRAWN","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2025-06-30","conditions":"Muscular Dystrophies, Limb-Girdle","enrollment":""},{"nctId":"NCT03834506","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":1030},{"nctId":"NCT05673785","phase":"PHASE2","title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-02-10","conditions":"Lymphoma","enrollment":52},{"nctId":"NCT06700798","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial","status":"RECRUITING","sponsor":"Fei Li","startDate":"2024-12-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":90},{"nctId":"NCT05401214","phase":"","title":"Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT03072238","phase":"PHASE3","title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-30","conditions":"Metastatic Prostate Cancer","enrollment":1101},{"nctId":"NCT06633419","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT06971211","phase":"PHASE2","title":"Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC","status":"RECRUITING","sponsor":"Jianbin Bi","startDate":"2024-11-27","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT06959732","phase":"PHASE2","title":"Zanubrutinib Combined With G-CVP in Previously Untreated FL","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-01","conditions":"Follicular Lymphoma ( FL)","enrollment":40},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT02025010","phase":"PHASE2","title":"Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-01-27","conditions":"Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT04598477","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","status":"TERMINATED","sponsor":"argenx","startDate":"2021-07-15","conditions":"Pemphigus Vulgaris, Pemphigus Foliaceus","enrollment":183},{"nctId":"NCT06890832","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jina Pharmaceuticals Inc.","startDate":"2025-05","conditions":"Metastatic Castration-resistant Prostate Cancer, MCRPC","enrollment":75},{"nctId":"NCT06635720","phase":"PHASE3","title":"REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)","status":"RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2024-11-01","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome","enrollment":50},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT06597682","phase":"NA","title":"Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03","conditions":"Post-acute Sequelae of SARS-COV-2 Infection","enrollment":632},{"nctId":"NCT05591144","phase":"NA","title":"Short-term Oral Prednisone for Acute Subjective Tinnitus","status":"COMPLETED","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-10-30","conditions":"Tinnitus, Subjective","enrollment":146},{"nctId":"NCT06838559","phase":"PHASE4","title":"Clinical Trial on 7-day Followed by Maintenance Therapy for 10 Weeks vs. 14-day and no Maintenance Course of Prednisolone for the Treatment of Infantile Epileptic Spasms Syndrome (IESS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colombo","startDate":"2025-01-01","conditions":"Spasms, Infantile, Prednisolone","enrollment":182},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT00887198","phase":"PHASE3","title":"Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-04-28","conditions":"Prostate Cancer","enrollment":1088},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":93},{"nctId":"NCT04410536","phase":"PHASE4","title":"Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2020-06-15","conditions":"Migraine, Hemicrania","enrollment":25},{"nctId":"NCT05578976","phase":"PHASE3","title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-02-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":900},{"nctId":"NCT05201248","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT04812366","phase":"PHASE2","title":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-09-21","conditions":"Prostate Cancer","enrollment":315},{"nctId":"NCT02506192","phase":"PHASE2","title":"Gulf War Illness Inflammation Reduction Trial","status":"COMPLETED","sponsor":"Minneapolis Veterans Affairs Medical Center","startDate":"2015-07","conditions":"Chronic Inflammation, Chronic Pain, Fatigue","enrollment":83},{"nctId":"NCT01650194","phase":"PHASE2","title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT03593759","phase":"PHASE3","title":"Cardiac Sarcoidosis Randomized Trial","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-01-15","conditions":"Cardiac Sarcoidosis, Sarcoidosis","enrollment":194},{"nctId":"NCT06697535","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)","status":"RECRUITING","sponsor":"Guangzhou JOYO Pharma Co., Ltd","startDate":"2023-05-24","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":35},{"nctId":"NCT06566989","phase":"PHASE1","title":"A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-19","conditions":"Metastatic Prostate Cancer","enrollment":8},{"nctId":"NCT06647940","phase":"PHASE2","title":"Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":39},{"nctId":"NCT06554639","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-11","conditions":"Prostatic Neoplasms","enrollment":12},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT04598451","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","status":"COMPLETED","sponsor":"argenx","startDate":"2020-12-01","conditions":"Pemphigus Vulgaris, Pemphigus Foliaceus","enrollment":222},{"nctId":"NCT06329830","phase":"PHASE1, PHASE2","title":"177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2024-10","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT04907227","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-23","conditions":"Prostatic Neoplasms","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["immediate release prednisone tablets"],"phase":"phase_3","status":"active","brandName":"Cortancyl Oral Tablet","genericName":"Cortancyl Oral Tablet","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cortancyl is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Hematologic malignancies and lymphomas (as adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}